• Explore /
  • Poster
  • / Efficacy of vemurafenib (V) a selective <sup>V600E</sup>BRAF inhibitor, as monotherapy or in combination with erlotinib (Erl) or erbitux (Erb) and irinotecan (Iri) doublets and triplets in a colorectal cancer (CRC) xenograft model.

Efficacy of vemurafenib (V) a selective V600EBRAF inhibitor, as monotherapy or in combination with erlotinib (Erl) or erbitux (Erb) and irinotecan (Iri) doublets and triplets in a colorectal cancer (CRC) xenograft model.

Abstract Poster

Authors

null

Brian Higgins

Pharma Research and Early Development, Hoffmann-La Roche Inc., Nutley, NJ

Brian Higgins , Kenneth Daniel Kolinsky , Kathleen Schostack , Gideon Bollag , Richard J. Lee , Fei Su , Kathryn Packman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Cancers of the Colon and Rectum

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Translational Research

Citation

J Clin Oncol 30, 2012 (suppl 4; abstr 494)

DOI

10.1200/jco.2012.30.4_suppl.494

Abstract #

494

Poster Bd #

C17

Abstract Disclosures

Similar Posters

First Author: LI Liu

First Author: Brian Higgins

First Author: Erkut Borazanci

First Author: Tianqi An